Clinical Trials Logo

Direct-acting Antivirals clinical trials

View clinical trials related to Direct-acting Antivirals.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03197155 Completed - Clinical trials for Hepatocellular Carcinoma

Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence

RECAR
Start date: June 1, 2016
Phase: N/A
Study type: Observational

Background and Aims: Arrival of direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) with high-sustained virological response (SVR) rates and very few side effects has drastically changed the management of HCV infection. The impact of DAA exposure on hepatocellular carcinoma (HCC) recurrence after a first remission in patients with advanced fibrosis remains to be clarified. Methods: 68 consecutive HCV patients with a first HCC diagnosis and under remission, subsequently treated or not with a DAA combination, were included. Clinical, biological, and virological data were collected at first HCC diagnosis, at remission and during the surveillance period.